[Lilly Biotechnology Center campus of an American pharmaceutical company Eli Lilly and Company] Michael Vi A US judge on Monday denied Novo Nordisk’s (NVO [https://seekingalpha.com/symbol/NVO]) bid to halt Eli Lilly’s (LLY [https://seekingalpha.com/symbol/LLY]) weight-loss drug advertisements, which the Danish pharmaceutical company alleged were false and misleading, in a market generating tens of billions of dollars in annual sales. US District Judge Zahid Quraishi in Trenton, New Jersey, said Novo Nordisk did not deserve a preliminary injunction, having failed to show that Eli Lilly's ads threatened sales, undermined its goodwill, or caused lasting damage to its clinical reputation, according to a media report.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.